A phase II clinical trial of carboplatin combined with the cox inhibitor, piroxicam, was performed in 31 dogs with naturally occurring, histopathologically confirmed, measurable TCC.
Complete tumour staging was performed before and at 6-week intervals during therapy. Tumour responses in 29 dogs included 11 partial remissions, 13 stable disease and five progressive disease.
Two of the 31 dogs were withdrawn prior to the re-staging of the tumour. Gastrointestinal toxicity was observed in 23 dogs.
Hematologic toxicity was noted in 11 dogs.
The median survival was 161 days from first carboplatin treatment to death.
In conclusion, carboplatin/piroxicam induced remission in 40% of dogs providing evidence that a cox inhibitor enhances the antitumour activity of carboplatin.
The frequent toxicity and limited survival, however, do not support the use of this specific protocol against TCC.
Source: Boria, P. A., Glickman, N. W., Schmidt, B. R., Widmer, W. R., Mutsaers, A. J., Adams, L. G., Snyder, P. W., DiBernardi, L., de Gortari, A. E., Bonney, P. L. & Knapp, D. W. (2005): Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. In: Veterinary and Comparative Oncology 3 (2), 73-80.
Tell a friend
|
Print version
|
Send this article
|
